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Abstract
Background
Protein may have both beneficial and detrimental effects on bone health depending on a
variety of factors, including protein source.
Objective
The aim was to conduct a systematic review and meta-analysis evaluating the effects of ani-
mal versus plant protein intake on bone mineral density (BMD), bone mineral content (BMC)
and select bone biomarkers in healthy adults.
Methods
Searches across five databases were conducted through 10/31/16 for randomized controlled
trials (RCTs) and prospective cohort studies in healthy adults that examined the effects of
animal versus plant protein intake on 1) total body (TB), total hip (TH), lumbar spine (LS) or
femoral neck (FN) BMD or TB BMC for at least one year, or 2) select bone formation and
resorption biomarkers for at least six months. Strength of evidence (SOE) was assessed and
random effect meta-analyses were performed.
Results
Seven RCTs examining animal vs. isoflavone-rich soy (Soy+) protein intake in 633 healthy
peri-menopausal (n = 1) and post-menopausal (n = 6) women were included. Overall risk of
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bias was medium. Limited SOE suggests no significant difference between Soy+ vs. animal
protein on LS, TH, FN and TB BMD, TB BMC, and bone turnover markers BSAP and NTX.
Meta-analysis results showed on average, the differences between Soy+ and animal protein
groups were close to zero and not significant for BMD outcomes (LS: n = 4, pooled net %
change: 0.24%, 95% CI: -0.80%, 1.28%; TB: n = 3, -0.24%, 95% CI: -0.81%, 0.33%; FN:
n = 3, 0.13%, 95% CI: -0.94%, 1.21%). All meta-analyses had no statistical heterogeneity.
Conclusions
These results do not support soy protein consumption as more advantageous than animal
protein, or vice versa. Future studies are needed examining the effects of different protein
sources in different populations on BMD, BMC, and fracture.
Trial registration
Clinical trial registry number and website: PROSPERO registry #: CRD42015017751 http://
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015017751.
Introduction
Bone undergoes continuous remodeling; therefore, adequate supply of amino acid and mineral
substrate are needed to support the formation of new bone. Protein has been identified as being
both beneficial and detrimental to bone health depending on a variety of factors including the
type of protein in the diet, the protein source, calcium intake, the population (i.e., older, gender),
weight loss, and/or the acid-base balance of the diet [1]. Dietary protein has long been known
to increase renal calcium excretion [2]. This increase in urinary calcium is a result of buffering
the metabolic acid load of dietary sulfur-containing amino acids largely present in animal-de-
rived proteins by releasing alkaline stores (e.g., calcium salts) from bone. More recently, it has
been shown with dual stable calcium isotope and balance studies that the increase in urinary cal-
cium can be accounted for by improved absorption efficiency with no change in calcium bal-
ance [3–5]. If the lack of difference in calcium absorption and balance with protein intake in
short term studies is assumed to persist long term, there may be no difference in bone mineral
density (BMD) due to dietary protein level or type.
In our recent systematic review, commissioned by the National Osteoporosis Foundation
(NOF), we reported the effect of level of dietary protein on bone. We concluded that low to
moderate evidence suggests no adverse effects of higher compared with lower total protein
intake on bone BMD outcomes. Only the lumbar spine BMD had moderate evidence support-
ing benefits of higher protein intake. There was moderate evidence that there was no relation
between higher vs lower protein intake and hip fractures, but inadequate evidence for all other
long-term fracture or fall outcomes [6].
Here we report the effect of source of protein (animal vs. plant) on bone health. Intakes of
several amino acids, including alanine and glycine, have been associated with higher BMD inde-
pendent of an individual’s genetic background [7]. In particular, aromatic amino acids found at
higher levels in animal-derived proteins have been suggested to increase calcium absorption
through their binding to the calcium sensing receptor (CaR) [8]. However, the effects of animal
versus plant proteins that contain dissimilar amino acid profiles remains a subject of great de-
bate; some plant proteins have the potential of producing more mEq of sulfuric acid per g of
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protein than some animal proteins (e.g., wheat vs. beef). Therefore, the NOF commissioned an
extended systematic review of the scientific literature on this research question so that clear evi-
dence-based public health recommendations may be developed for consumers. However, due
to the paucity of studies examining this research question, it is important to note that the
included intervention studies focus only on soy protein as the plant protein source of interest.
Methods
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) state-
ment was followed in reporting this systematic review [9]. A prospectively developed protocol
for this systematic review was registered on PROSPERO [10]. The materials and methods are
described in a previous paper [6]. Search strategies were developed in consultation with two
librarians. The initial strategy was developed for Ovid Medline1 (1946 to week 4 October
2016) and then adjusted for four additional electronic databases: Cochrane Central Register of
Controlled Trials (1991 to 31 October 2016), Scopus (+ EMBASE 1974 to 31 October 2016),
Web-of-Science (1864 to 31 October 2016) and Global Health (1910 to 31 October 2016). All
searches were limited to the English language and human studies that examined the relation-
ships of dietary protein intake (via foods or supplements) on bone health outcomes of interest.
The complete search strategy is presented in S1 Table).
Study eligibility criteria
We included intervention trials that compared equal amounts of dietary protein from dif-
ferent sources (animal vs. plant) and prospective cohort studies that examined different
doses of dietary protein intake (i.e., animal and plant protein intake) and their effects on
bone health outcomes of interest in healthy adults  18 years of age. We excluded studies
comparing varying doses of protein intake from the same source (i.e., high vs. low total
protein intake, covered in a previous review [6]). Healthy adults were defined as “healthy
obese” adults; those with past or current fractures but no other pre-existing conditions;
older adults with sarcopenia or frailty but no other clear disease (e.g., renal disease); and
adults 45 years of age with hypertension, due to its higher prevalence among older adults
[11]. We excluded studies among children and adolescents (i.e., less than 18 years of age),
pregnant or lactating women, participants who were all diagnosed with a particular disease
(e.g., 100% of participants with type 2 diabetes), and studies where > 20% of the baseline
population had a disease. Outcomes of interest included: BMD, total body bone mineral
content (BMC), and bone fracture or fracture risk of any site in studies  one year in dura-
tion, as defined in previous studies [12]; falls; and biomarkers for bone metabolism, miner-
alization, formation, turnover or resorption if the study was  six months in duration. As
studies among those <18 years of age were excluded, we excluded bone development out-
comes. The complete list of bone health outcomes is described in Table 1.
Study selection process
Citations identified from the non-Medline databases were first title-screened by a single inves-
tigator to exclude in vitro, cell and stem cell studies, animal studies, cross-sectional studies, ret-
rospective case-control studies, interrupted time series studies, meta-analyses, and review
articles. Next, all abstracts identified in the literature searches were independently screened by
two or more investigators using Abstrackr™ [13]. Full-text articles were retrieved for all poten-
tially relevant abstracts and independently screened by two investigators based on eligibility
criteria. In any instance where studies were conducted in the same cohort population and time
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period, the first published study was retained. All screening conflicts were resolved via consen-
sus by the entire research team.
Data extraction
The data extraction forms used in a previous systematic review evidence report [12] were modi-
fied for our topic of interest. The following items were extracted: study characteristics, baseline
population characteristics, background diet data, dietary assessment methods, interventions
(for intervention studies only), confounders and effect modifiers used in statistical analysis, rele-
vant outcomes assessed, and results (complete data extraction forms are available upon request).
Results were extracted quantitatively when reported and, when absent, qualitatively results were
extracted. For all studies, in order of preference, multivariate adjusted analyses were extracted
over age adjusted or crude measures and risk and hazard ratios over incidence ratios and odds
ratios. Each study was extracted by one investigator and reviewed and confirmed by a second
investigator. Any disagreements were resolved via group consensus.
Risk of bias (ROB) in individual studies
Intervention studies’ methodological quality were assessed using a modified version of the
Cochrane risk of bias (ROB) tool [14]. This tool was modified for nutrition and outcome-spe-
cific items and addressed risk of selection bias, performance bias, detection bias, attrition bias,
reporting bias, and other potential biases. Two investigators independently conducted ROB
assessments and any disagreements resolved via group consensus. It is important to note that
certain categories were given greater weight when deciding on overall ratings. For example, an
unclear rating for blinding of outcome assessors was given less weight for outcomes with objec-
tive measurements (e.g., fractures confirmed by x-ray or BMD outcomes measured clinically).
Data synthesis
All included studies were summarized in narrative form and in summary tables that tabulated
key features of the study populations, design, intervention, outcomes, and results. Summary
tables were organized by study type (i.e., randomized control trial (RCT) vs. cohort study) and
study results were qualitatively and quantitatively summarized first by outcome of interest,
then by group comparison (isoflavone-rich soy protein vs. animal protein and, where applica-
ble, isoflavone-poor soy protein vs. animal protein and isoflavone-rich soy protein vs. isofla-
vone-soy protein).
Table 1. Included bone outcomes of interest1,2.
◦ Bone mineral content (BMC): total body (TB) only
◦ Bone mineral density (BMD): TB, total hip (TH), femoral neck (FN), lumbar spine (LS)
◦ Fracture: all sites
◦ Falls
◦ Bone quality
◦ Bone metabolism biomarkers2 bone-specific alkaline phosphatase (BSAP), collagen type 1 cross-linked C-terminal
telopeptide (CTX), collagen type 1 cross-linked N-telopeptide (NTX), deoxypyridinoline (DPD)
1 The following outcomes were included outcomes of interest, but were not reported in the included studies: bone
quality (e.g., via amplitude-dependent speed of sound (Ad-SOS), bone sialoprotein (BSP), tartrate-resistant acid
phosphatase 5b, osteocalcin (OC), alkaline phosphatase (ALP), C- or N-terminal type 1 procollagen (C1NP or
P1NP), hydroxyproline, pyridinoline (PYD)
2 Ratios of the biomarkers (e.g., with creatinine) were included as outcomes of interest
https://doi.org/10.1371/journal.pone.0192459.t001
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Qualitative synthesis. The strength of evidence (SOE) for major comparisons and out-
comes was assessed through a consensus process of the entire research team, using a modified
version of the NOFs evidence grading system [15] and the grading system utilized by the Amer-
ican Diabetes Association and other prominent groups [15–17]. As detailed previously [6], SOE
levels used were A (Strong), B (Moderate), C (Limited), D (Inadequate), E (Expert Consensus
or Clinical Experience), or NA (not applicable).
Meta-analysis (quantitative synthesis). The methods outlined in the Cochrane Hand-
book for conducting meta-analysis of RCTs were followed [18].
For eligible BMD outcomes in RCTs, we used the reported or calculated net percentage
change between the animal and plant protein groups as the effect size measure in the meta-
analysis because most of RCTs reported within-group percentage changes in BMD out-
comes. The mean within-group percentage change, if not reported, was calculated using
post-intervention mean minus baseline mean, then divided by baseline mean and multi-
plied by 100%. Its standard deviation (SD) was estimated using the SD of the mean change
divided by the baseline mean. The net percentage change was the difference in the within-
group percentage changes of the two groups using the animal protein group as the reference
group. Thus, a positive net percentage change indicates an effect (i.e., less bone loss) favor-
ing plant protein intake. The SD of the net percentage change was the pooled SD of the two
SDs of the mean change: SDpooled =
p
(((n1−1) x SD1 + (n2−1) x SD2) / (n1 + n2−2)) where
n1 and n2 are the sample sizes, and SD1 and SD2 are the SDs of the mean within-group per-
centage change of the plant and animal protein groups, respectively. For the one study [19]
that did not report final sample sizes, the baseline sample size was used in our calculations.
We assumed a correlation coefficient (Corr) value of 0.50 to impute the missing SD of the
mean within-group change. Sensitivity analyses using Corr values of 0.20 and 0.80 were
conducted to evaluate the impacts of the correlation assumptions on the meta-analysis
results, and none showed appreciable impacts (S2 Table).
In light of clinical heterogeneity (different doses of protein interventions), we performed ran-
dom-effects meta-analyses for outcomes with at least three unique RCTs [20]. We used both the
Q statistic (considered significant when the P value was less than 0.10) and the I2 index to quan-
tify the extent of statistical heterogeneity [18]. We defined low, moderate and high heterogeneity
as I2 values of 25%, 50% and 75%, respectively. These cutoffs are arbitrary and were used for de-
scriptive purposes only [21]. Studies were excluded from meta-analyses if required information
for the aforementioned calculations were not reported for any given outcome. One original
author was contacted to obtain missing quantitative data needed for meta-analysis, but the data
were no longer available [22].
All calculations and meta-analyses were conducted in Stata SE 13 (Stata Corp). The analyti-
cal datasets can be found in the S1 File. Two-tailed P values less than 0.05 were considered sta-
tistically significant.
Results
Our search yielded 1,767 citations for dual abstract screening, of which 222 were identified for
full-text screening and seven RCTs were finally included. No cohort studies met the eligibility
criteria. Details of the literature search and study selection flow are summarized in Fig 1. Ten
prospective cohort studies were excluded because there were no analyses directly comparing
animal to plant protein intake in relation to the outcomes of interest. However, the results
from these cohort studies are briefly described in the end of result section to summarize the
associations between varying intakes of plant or animal protein and long-term bone health
outcomes as supplementary information to the findings from RCTs.
Protein source and bone health systematic review
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Characteristics of RCTs
Seven RCTs [19, 22–27] that met the eligibility criteria all compared soy protein to animal pro-
tein intake in generally healthy peri- or postmenopausal women (Table 2). A total of 803 and
633 women were enrolled in the studies and analyzed, respectively. Though all plant protein
sources administered in these studies were soy protein, animal protein sources were not uniform
across studies: five [19, 22, 25–27] administered milk protein (whey with or without casein pro-
tein), one [23] administered a mix of milk and egg white protein, and one [24] administered an
unspecified, non-soy protein. Furthermore, protein doses administered varied across studies:
one [23] gave participants 18 g protein/d, four [19, 24, 25, 27] gave 25–25.6 g protein/d, and two
supplemented with higher doses of 38 g protein/d [26] and 40 g protein/d [22]. Calcium supple-
ment doses also varied by study. One study [23] only supplemented 315 mg calcium/d to partici-
pants unable to achieve dietary intakes of 1200–1500 mg calcium/d. A second study [25] did not
specify the calcium dosage supplemented to all participants. All participants in the remaining
five studies [19, 22, 24, 26, 27] received calcium supplementation ranging from 500–1200 mg/d.
The intervention durations ranged from 6 to 24 months.
In addition to assessing protein intervention doses, six studies [19, 22–25, 27] also exam-
ined participants’ diets via food diaries, 24-hour recalls, or food frequency questionnaires.
There was no significant difference in dietary calcium intake between groups at baseline
[19, 22–25, 27]. Among these, five studies reported dietary protein intake at baseline [19,
23–25, 27]. One study [27] reported that, though total protein intake was similar at baseline
across groups, the milk protein group had a significantly greater increase in total protein
intake (+27.9 g protein/d) post-intervention compared to the SPI- and SPI+ protein groups
Fig 1. Literature search and study selection process.
https://doi.org/10.1371/journal.pone.0192459.g001
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(+12.5 and +14.5 g, respectively). In a second study [24], there was a significant difference
in total protein intake between groups at baseline but not post-intervention. There were no
significant differences in total protein intake between groups at baseline nor post-interven-
tion in the other three studies [19, 23, 25].
Four studies reported BMD as a primary outcome [19, 22–25, 27]. Five studies reported
biomarkers among their primary outcomes, while one [22] reported them as secondary out-
comes and the seventh study [25] did not specify. Of the seven studies, three reported power
calculations [22, 25, 27]. ROB assessments for individual RCTs are described in S3 Table.
Results are organized first by outcome and then by group comparisons: isoflavone-rich soy
vs. animal protein (i.e., our main question of interest) (N = 7); isoflavone-poor soy protein vs.
animal protein (N = 3) [22, 23, 27]; and isoflavone-rich soy vs. isoflavone-poor soy protein
(N = 3) [22, 23, 27]. No RCTs examined falls or fracture outcomes.
LS BMD
Four RCTs [23–25, 27] examined isoflavone-rich soy protein vs. animal protein’s effect on LS
BMD Of these, two RCTs [23, 27] had a third, isoflavone-poor soy protein group, and thus also
contributed data on the comparison between isoflavone-poor soy protein to animal protein as
well as on the comparison between isoflavone-poor and isoflavone-rich soy protein. Three stud-
ies administered similar protein doses of 25g/d [24, 27] and 25.6 g/d [25] in the form of a sup-
plement powders to mix with food or beverages [25, 27] or both food and supplement powder
[24], while the fourth study administered supplement powders containing 18g protein/d to mix
with a food or beverage [23]. Administered doses of isoflavones in the soy protein groups ran-
ged from 35-97mg/d, and animal protein sources varied across studies. Overall ROB was me-
dium, due to low compliance in one study (<80%) [24] and incomplete outcome data in two
studies (dropout rate>20% or no comparison between study completers and dropouts in per
protocol analysis) [23, 24] (S3 Table).
None of the four RCTs comparing isoflavone-rich soy protein and animal protein intake
found a significant difference in the net changes in LS BMD over one to two years (Table 3).
The random-effects meta-analysis of the four RCTs in a total of 393 postmenopausal women
also showed no difference in the effects of isoflavone-rich soy protein vs. animal protein intake
on LS BMD, with no statistical heterogeneity (pooled mean percentage change: 0.24%, 95%
CI: -0.80%, 1.28%, I2: 0.0%) (Fig 2).
In the two three-arm RCTs [23, 27] comparing isoflavone-poor soy protein to animal pro-
tein and comparing isoflavone-rich to isoflavone-poor soy protein in 393 and 146 postmeno-
pausal women, respectively, no significant differences in the net changes in LS BMD were
found (Table 3).
TH BMD
Two RCTs [24, 25] examined isoflavone-rich soy protein vs. animal protein’s effect on TH
BMD in a total of 237 postmenopausal women. Both studies were one year in duration and
administered protein via supplement powders to mix with a beverage in similar doses: 25 g
protein/d [24] and 25.6 g protein/d [25]. Administered doses of isoflavones in the soy pro-
tein groups were 60 mg/d [24] and 97 mg/d [25]. The animal protein source was milk pro-
tein in one study [25] and an unspecified, non-soy protein in the second study [24]. Overall
ROB was medium due to low compliance (<80%) and incomplete outcome data (i.e., drop-
out rate >20%) in one study [24] (S3 Table). Neither RCT comparing isoflavone-rich soy
protein to animal protein intake found a significant difference in the net changes in TH
BMD (Table 3).
Protein source and bone health systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0192459 February 23, 2018 9 / 24
Table 3. RCT BMD and BMC results comparing isoflavone-rich soy protein, isoflavone-poor soy protein, and animal protein1.
Study Year [ref] Outcome
(units)
Soy Protein (SP)
(SPI+/ SPI-)
Comparator Protein
(CP) (AP/ SPI-)
Study
Length
SP
n
CP
n
SP Mean
at BL
CP Mean
at BL
Net
change
95% CI P-
value
Kenny 2009 [23] BMD FN (g/
cm2)
SPI+ Milk+egg white 1 y 25 22 0.809 0.8 0.50% -1.79%,
2.79%
>0.05
SPI- Milk+egg white 1 y 24 22 0.861 0.8 0.49% -1.18%,
2.16%
>0.05
SPI+ SPI- 1 y 25 24 0.809 0.861 0.007% -2.24%,
2.26%
>0.05
Kreijkamp-Kaspers
2004 [25]
BMD FN (g/
cm2)
SPI+ Milk 1 y 88 87 0.722 0.695 0.02% -4.35%,
4.39%
0.89
Vupadhyayula 2009
[27]
BMD FN (g/
cm2)
SPI+ Milk 2 y 57 52 0.873 0.881 0.03% -1.23%,
1.29%
>0.05
SPI- Milk 2 y 48 52 0.865 0.881 -0.92% -2.19%,
0.35%
>0.05
SPI+ SPI- 2 y 57 48 0.873 0.865 0.95% -2.40%,
4.30%
>0.05
Arjmandi 2005 [24] BMD LS1-4
(g/cm2)
SPI+ Non-soy AP 1 y 35 27 0.944 0.941 -0.21%2 -7.29%,
6.88%
0.958
Kenny 2009 [23] BMD LS2-4
(g/cm2)
SPI+ Milk+egg white 1 y 25 22 1.127 1.11 -0.55% -2.54%,
1.45%
>0.05
SPI- Milk+egg white 1 y 24 22 1.218 1.11 -0.82% -2.60%,
0.97%
>0.05
SPI+ SPI- 1 y 25 24 1.127 1.218 0.27% -1.75%,
2.30%
>0.05
Kreijkamp-Kaspers
2004 [25]
BMD LS1-4
(g/cm2)
SPI+ Milk 1 y 88 87 0.917 0.895 0.44% -4.81%,
5.70%
0.79
Vupadhyayula 2009
[27]
BMD LS1-4
(g/cm2)
SPI+ Milk 2 y 57 52 1.085 1.104 0.56% -0.71%,
1.83%
>0.05
SPI- Milk 2 y 48 52 1.076 1.104 1.17% -0.10%,
2.44%
>0.05
SPI+ SPI- 2 y 57 48 1.085 1.076 -0.61% -6.00%,
4.78%
>0.05
Arjmandi 2005 [24] BMD TH (g/
cm2)
SPI+ Non-soy AP 1 y 35 27 0.853 0.871 -0.002%2 -6.28%,
6.28%
0.512
Kreijkamp-Kaspers
2004 [25]
BMD TH (g/
cm2)
SPI+ Milk 1 y 88 87 0.861 0.831 0.49% -3.60%,
4.57%
0.27
Arjmandi 2005 [24] BMD TB (g/
cm2)
SPI+ Non-soy AP 1 y 35 27 1.05 1.05 0.000%2 -5.03%,
5.03%
0.986
Kenny 2009 [23] BMD TB (g/
cm2)
SPI+ Milk+egg white 1 y 25 22 1.106 1.086 -0.17% -1.06%,
072%
>0.05
SPI- Milk+egg white 1 y 24 22 1.129 1.086 0.20% -.56%,
0.95%
>0.05
SPI+ SPI- 1 y 25 24 1.106 1.129 -0.37% -1.25%,
0.51%
>0.05
Vupadhyayula 2009
[27]
BMD TB (g/
cm2)
SPI+ Milk 2 y 57 52 1.113 1.127 -0.29% -1.03%,
0.45%
>0.05
SPI- Milk 2 y 48 52 1.114 1.127 0.08% -0.82%,
0.66%
>0.05
SPI+ SPI- 2 y 57 48 1.113 1.114 -0.21% -2.83%,
2.41%
>0.05
Arjmandi 2005 [24] BMC TB (g) SPI+ Non-soy AP 1 y 35 27 2023 2022 0.40%2 -6.96%,
7.76%
0.944
1 AP, animal protein; BMC, bone mineral content; BMD, bone mineral density; CI, confidence interval; CP, comparator protein; FN, femoral neck; LS, lumbar spine;
RCT, randomized controlled trial; SP, soy protein; SPI-, isoflavone-poor soy protein SPI+, isoflavone-rich soy protein; TB, total body; TH, total hip.
2 Imputation was used to calculate net change, r = 0.50
https://doi.org/10.1371/journal.pone.0192459.t003
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FN BMD
Three RCTs [23, 25, 27] examined isoflavone-rich soy protein vs. animal protein’s effect on FN
BMD. Of these, two RCTs [23, 27] had a third, isoflavone-poor soy protein group, and thus
also contributed data on the comparison between isoflavone-poor soy protein to animal pro-
tein as well as on the comparison between isoflavone-poor and isoflavone-rich soy protein.
Two studies administered 25g protein/d via supplement powders to mix with a beverage and
administered milk protein as the source of animal protein [25, 27], while a third study admin-
istered 18g protein/d via supplement powders to mix with a food or beverage and adminis-
tered an egg white-milk protein mix as the source of animal protein [23]. Administered doses
of isoflavones in the soy protein groups ranged from 35-97mg/d and study duration ranged
from one to two years. Overall ROB was low, though it is important to note one study [23] did
have incomplete outcome data (dropout rate >20% with no comparison between study com-
pleters and dropouts in per protocol analysis) (S3 Table).
None of the three RCTs [23, 25, 27] comparing isoflavone-rich soy protein and animal pro-
tein intake found a significant difference in the net changes in FN BMD over one to two years
(Table 3). The random-effects meta-analysis of the three RCTs in a total of 331 postmenopa-
usal women also showed no difference in the effects of isoflavone-rich soy protein vs. animal
protein intake on FN BMD, with no statistical heterogeneity (pooled mean percentage change:
0.13%, 95% CI: -0.94%, 1.21%, I2: 0.0%) (Fig 3).
In the two, three-arm RCTs [23, 27] comparing isoflavone-poor soy protein to animal
protein and comparing isoflavone-rich to isoflavone-poor soy protein in 146 and 154
Fig 2. Effect of isoflavone-rich soy protein vs. animal protein intake on lumbar spine BMD in postmenopausal women.
https://doi.org/10.1371/journal.pone.0192459.g002
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postmenopausal women, respectively, no significant differences in the net changes in FN
BMD were found (Table 3).
TB BMD
Three RCTs [23, 24, 27] examined isoflavone-rich soy protein vs. animal protein’s effect on TB
BMD. Of these, two RCTs [23, 27] had a third, isoflavone-poor soy protein group, and thus
also contributed data on the comparison between isoflavone-poor soy protein to animal pro-
tein as well as on the comparison between isoflavone-poor and isoflavone-rich soy protein.
Protein dose and administration varied: two [24, 27] administered a supplement of 25 g pro-
tein/d to mix with a beverage and one study [23] administered 18g protein/d to mix with a
food or beverage. Administered doses of isoflavones in the soy protein groups ranged from
35–90 mg/d, and animal protein sources varied across studies. Overall ROB was medium, due
to low compliance in one study (<80%) [23] and incomplete outcome data in two studies (i.e.,
dropout rate>20%) [23, 24] (S3 Table).
None of the three RCTs comparing isoflavone-rich soy protein to animal protein found a
significant difference in the net changes in TB BMD over one to two years (Table 3). The ran-
dom-effects meta-analysis of the three RCTs in a total of 218 postmenopausal women also
showed no difference in the effects of isoflavone-rich soy protein vs. animal protein intake on
TB BMD, with no statistical heterogeneity (pooled mean percentage change: -0.24%, 95% CI:
-0.81%, 0.33%, I2: 0.0%) (Fig 4).
Fig 3. Effect of isoflavone-rich soy protein vs. animal protein intake on femoral neck BMD in postmenopausal women.
https://doi.org/10.1371/journal.pone.0192459.g003
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In the two three-arm RCTs [23, 27] comparing isoflavone-poor soy protein to animal pro-
tein and comparing isoflavone-rich to isoflavone-poor soy protein in 146 and 154 postmeno-
pausal women, respectively, no significant differences in the net changes in TB BMD were
found (Table 3).
TB BMC
Only one twelve-month RCT [24] examined isoflavone-rich soy protein vs. animal protein’s
effect on TB BMC in 62 postmenopausal women. The study administered 25g soy (with 60 mg
isoflavones/d) vs. unspecified, non-soy protein/d via both food and supplement powders to
mix with a beverage, and did not find a significant difference in the net changes in TB BMC
after one year (Table 3). However, the ROB for this RCT [24] was high, due to low compliance
(<80%) and incomplete outcome data (i.e., dropout rate>20%) (S3 Table).
BSAP
Five RCTs [19, 22–25] examined isoflavone-rich soy protein vs. animal protein’s effect on
BSAP levels in 372 peri- and postmenopausal women. Of these, two RCTs [22, 23] had a
third, isoflavone-poor soy protein group, and thus also contributed data on the compari-
son between isoflavone-poor soy protein to animal protein as well as on the comparison
between isoflavone-poor and isoflavone-rich soy protein. Protein administration varied
across studies: two studies [22, 25] administered a supplement powder to mix with a bev-
erage, one administered a supplement powder to mix with a food or beverage[23], one
Fig 4. Effect of isoflavone-rich soy protein vs. animal protein intake on total body BMD in postmenopausal women.
https://doi.org/10.1371/journal.pone.0192459.g004
Protein source and bone health systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0192459 February 23, 2018 13 / 24
administered both food and a supplement powder, and one administered a protein bever-
age [19]. Protein doses ranged from 18–40g/d. Isoflavones in the soy protein groups ran-
ged from 35–97 mg/d and animal protein sources varied across studies. Overall ROB was
medium, as two [19, 24] had low compliance (<80%) and two studies [23, 24] had incom-
plete outcome data (i.e., dropout rate >20%) (S3 Table).
There was no significant difference between isoflavone-rich soy protein and animal protein
intake and changes in BSAP in one six-month [22] and three one-year RCTs [23–25] (Table 4).
One nine-month RCT [19] found those taking 25.6 g/d soy protein isolate plus 91.2 mg/d isofla-
vones had a significantly greater reduction in BSAP compared to those taking 25.6 g/d milk pro-
tein isolate (net change: 0.75 U/L, 95% CI 0.13, 1.37)).
In the two, three-arm RCTs [22, 23] comparing isoflavone-poor soy protein to animal pro-
tein and comparing isoflavone-rich to isoflavone-poor soy protein in 91 and 94 women,
respectively, no significant differences in the net changes in BSAP were found (Table 4).
NTX
Four RCTs [22, 23, 26, 27] examined isoflavone-rich soy protein vs. animal protein’s effect on
NTX levels in 162 peri- and postmenopausal women. Of these, three RCTs [22, 23, 27] had a third,
isoflavone-poor soy protein group, and thus also contributed data on the comparison between iso-
flavone-poor soy protein to animal protein as well as on the comparison between isoflavone-poor
and isoflavone-rich soy protein. Protein administration varied across studies: three studies [23, 26,
27] administered protein powder supplements and one study administered both protein powder
and food [22]. The protein doses in each study ranged from 18–40 g/d and, in the soy groups, iso-
flavones ranged from 35–120 mg/d. Animal protein groups received milk protein sources in three
studies [22, 26, 27] and an egg white-milk protein mix in one study [23]. Overall, ROB was me-
dium, as two studies [23, 26] had incomplete outcome data (dropout rate>20%) (S3 Table).
None of the four RCTs comparing isoflavone-rich soy protein to animal protein found a
significant difference in the net changes in NTX after six months to one year (Table 4). In the
two, three-arm RCTs [22, 23] comparing isoflavone-poor soy protein to animal protein and
comparing isoflavone-rich to isoflavone-poor soy protein in 133 and 144 women, respectively,
no significant differences in the net changes in NTX were found (Table 4).
C-terminal telopeptide of type 1 collagen (CTX)
One nine-month RCT [19] examined isoflavone-rich soy protein vs. animal protein’s effect on
CTX levels in 43 postmenopausal women. The ROB for this study [19] was medium, due to
low compliance (<80%) (S3 Table). The study administered a supplement powder containing
25.6g of soy to mix with a food or beverage vs. milk protein/d; the soy group also received a
tablet containing 91.2 mg isoflavones/d while the milk protein group received a placebo tablet.
The study found a significantly greater reduction in CTX in the isoflavone-rich soy group
compared to the milk protein group (net change: 3.3 ng/mL, 95% CI 0.695, 5.905; Table 4).
Deoxypyridinoline (DPD)
One twelve-month RCT [24] examined isoflavone-rich soy protein vs. animal protein’s effect
on DPD levels in 62 postmenopausal women. The overall ROB for this study [24] was medium,
due to low compliance (<80%) and incomplete outcome data (dropout rate>20%) (S3 Table).
The study administered protein supplements to mix with a beverage containing 25 g of soy
protein (with 60 mg isoflavones) vs. an unspecified, non-soy protein, and did not find a signifi-
cant difference in the net change in DPD between groups (net change = 0.16 nmol/mmol cre-
atinine, 95% CI -0.35, 0.66; Table 4).
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SOE Grading for RCTs
Evidence grading scores for soy isoflavone-poor protein, soy isoflavone-rich protein vs. ani-
mal protein intake by outcome are listed in Tables 5 and 6. No outcome received greater
than a C-level or “limited” evidence grade due to the limited number of RCTs and lack of
prospective cohort studies addressing each outcome. C-level evidence grade was assigned
Table 4. RCT biomarker results comparing isoflavone-rich soy protein, isoflavone-poor soy protein, and animal protein1.
Study Year [ref] Outcome (units) Soy Protein Group
(SPI+/SPI-)
Comparator Protein Group
(AP/ SPI-)
Study
Length
SP n CP n SP Mean at
BL
CP Mean at
BL
Net
change
95% CI P-
value
Alekel 2000 [22] BSAP (μg/L) SPI+ Whey 6 mo 24 21 NR NR No sig diff between groups
(p>0.05, data in figure only)
SPI- Whey 6 mo 24 21 NR NR No sig diff between groups
(p>0.05, data in figure only)
SPI+ SPI- 6 mo 24 24 NR NR No sig diff between groups
(p>0.05, data in figure only)
Arjmandi 2005 [24] BSAP (U/L) SPI+ Non-soy AP 1 y 35 27 19.8 19.8 -0.402 -3.59,
2.79
0.796
Evans 2007 [19] BSAP (U/L) SPI+ MPI 9 mo 21 22 SPI: 32.6
SPI+Ex:
25.6
MPI: 25.3
MPI+Ex:
28.5
0.75 0.13,
1.37
0.03
Kenny 2009 [23] BSAP (U/L) SPI+ Milk+egg white 1 y 25 22 24.7 26.8 0.602 -4.61,
5.81
>0.05
SPI- Milk+egg white 1 y 24 22 21.2 26.8 -0.80 -5.22,
3.62
>0.05
SPI+ SPI- 1 y 25 24 24.7 21.2 1.40 -2.68,
5.48
>0.05
Kreijkamp-Kaspers
2004 [25]
BSAP (μg/L) SPI+ Milk 1 y 88 87 12.7 12.9 -0.23 -0.98,
0.53
0.55
Alekel 2000 [22] NTx (nmol BCE/ mmol
creatinine)
SPI+ Whey 6 mo 24 21 NR NR No sig diff between groups
(p>0.05, data in figure only)
SPI- Whey 6 mo 24 21 NR NR No sig diff between groups
(p>0.05, data in figure only)
SPI+ SPI- 6 mo 24 24 NR NR No sig diff between groups
(p>0.05, data in figure only)
Kenny 2009 [23] NTx (nmol BCE/ mmol
creatinine)
SPI+ Milk+egg white 1 y 25 22 37.5 37.5 0.902 -7.83,
9.63
>0.05
SPI- Milk+egg white 1 y 24 22 33.1 37.5 -0.40 -9.19,
8.39
>0.05
SPI+ SPI- 1 y 25 24 37.5 33.1 1.30 -7.01,
9.61
>0.05
Murray 2003 [26] NTx (nmol BCE) SPI+ Whey+casein 6 mo 8 7 18.5 16.8 -1.602 -6.91,
3.71
>0.05
Vupadhyayula 2009
[27]
NTx (nmol BCE) SPI+ Milk 2 y 25 30 NR NR 2.79 -1.98,
7.56
>0.05
SPI- Milk 2 y 22 30 NR NR 4.13 -1.99,
10.25
>0.05
SPI+ SPI+ 2 y 25 22 NR NR -1.34 -5.72,
3.04
>0.05
Arjmandi 2005 [24] DPD (nmol/mmol
creatinine)
SPI+ Non-soy AP 1 y 35 27 5.2 5.3 0.162 -0.35,
0.66
0.888
Evans 2007 [19] CTX (ng/mL) SPI+ MPI 9 mo 21 22 SPI: 0.61
SPI+Ex:
0.47
MPI: 0.49
MPI+Ex:
0.56
3.3 0.695,
5.905
0.02
1 BSAP, bone-specific alkaline phosphatase; CI, confidence interval; CTX, C-terminal telopeptide of type 1 collagen; diff, difference; DPD, deoxypyridinoline; MPI, milk
protein isolate; NR, not reported; NTX, N-terminal telopeptide of type I collagen; RCT, randomized controlled trial; sig, significant; SPI+, isoflavone-rich soy protein
isolate; SPI-, isoflavone-poor soy protein isolate.
2Imputation was used to calculate net change, r = 0.50
https://doi.org/10.1371/journal.pone.0192459.t004
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for LS, FN, and TB BMD and the bone turnover markers BSAP and NTX as only limited evi-
dence suggests no significant difference between isoflavone-poor protein vs. animal protein.
D-level evidence was assigned for CTX and DPD, as these outcomes were only examined
by one study each. C-level evidence grade was assigned for LS, TH, FN, and TB BMD, TB
BMC, and the bone turnover markers BSAP and NTX as only limited evidence suggests no
Table 5. SOE grading: equal amounts of soy, isoflavone-rich protein vs. animal protein intake by outcome1.
Outcome Studies (N, (Ref)) SOE
Grade
Explanation
RCTs Cohort
Studies
BMD LS 4
[23–25,
27]
0 C We conclude a C level of evidence that there is no significant difference
between soy vs. animal protein intake on BMD loss in postmenopausal
women. Four RCTs with medium ROB did not find a significant
difference between groups.
BMD TH 2
[24, 25]
0 C We conclude a C level of evidence that there is no significant difference
between soy vs. animal protein intake on BMD loss in postmenopausal
women. Two RCTs with medium ROB did not find a significant
difference between groups.
BMD FN 3
[23, 25,
27]
0 C We conclude a C level of evidence that there is no significant
difference between soy vs. animal protein intake on BMD loss in
postmenopausal women. Three RCTs with low ROB did not find a
significant difference between groups.
BMD TB 3
[23, 24,
27]
0. C We conclude a C level of evidence that there is no significant
difference between soy vs. animal protein intake on BMD loss in
postmenopausal women. Three RCTs with medium ROB did not find
a significant difference between groups.
BMC TB 1
[24]
0 D We conclude a D level of evidence that there is no significant
difference between soy vs. animal protein intake on TB BMC loss in
postmenopausal women. One RCT with medium ROB did not find a
significant difference between groups.
Falls 0 0 D There is insufficient data to support a hypothesis: no study examined
this association.
Fractures 0 0 D There is insufficient data to support a hypothesis: no study examined
this association.
BSAP 5
[19, 22–
25]
0 C We conclude a C level of evidence that there is no significant difference
between soy vs. animal protein intake on BSAP in postmenopausal
women. Four RCTs did not find a significant difference between groups.
One six-month RCT found the soy group had a significantly greater
reduction in BSAP compared to the milk protein group. ROB was
medium overall.
CTX 1
[19]
0 D We conclude a D level of evidence that soy protein causes a greater
reduction in CTX compared to milk protein in postmenopausal
women. Only one, 9-month RCT with medium ROB examined this
association and found a greater reduction in the soy protein group vs.
the milk protein group.
DPD 1
[24]
0 D We conclude a D level of evidence that there is no significant
difference between soy protein vs. animal protein intake on DPD in
postmenopausal women. Only one, one-year RCT with medium ROB
examined this association and did not find a significant difference.
NTX 4
[22, 23,
26, 27]
0 C We conclude a C level of evidence that there is no significant
difference between the effects of soy protein vs. animal protein intake
on NTX in postmenopausal women. Four RCTs with medium ROB
did not find a significant difference between groups.
1 BMD, bone mineral density; BMC, bone mineral content; BSAP, bone-specific alkaline phosphatase; CTX, C-
terminal telopeptide of type 1 collagen; DPD, deoxypyridinoline; FN, femoral neck; LS, lumbar spine; NTX, N-
terminal telopeptide of type 1 collagen; Ref, reference; TB, total body; TH, total hip; SOE, strength of evidence
https://doi.org/10.1371/journal.pone.0192459.t005
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significant difference between isoflavone-rich protein vs. animal protein. Several outcomes,
including fractures of any type, falls, CTX, DPD, and certain BMD sites were not reported
in any study and thus were assigned D-level or “inadequate” evidence grade. Several studies
also had “unclear” or “high” ROB assessments, which also factored into the evidence grad-
ing (S3 Table).
Findings from the prospective cohort studies
Given limited data from RCTs, we summarize key findings from the prospective cohort
studies to supplement the findings from RCTs. Ten cohort studies [28–37] examining the
associations between varying intakes of plant or animal protein and long-term bone health
Table 6. SOE grading: equal amounts of soy, isoflavone-poor protein vs. animal protein intake by outcome1.
Outcome Studies (N,
(Ref))
SOE
Grade
Explanation
RCTs Cohort
Studies
BMD LS 2
[23,
27]
0 C We conclude a C level of evidence that there is no significant difference
between soy protein vs. animal protein intake on BMD loss in
postmenopausal women. Two RCTs with low ROB comparing isoflavone-
poor soy protein vs. animal protein did not find significant associations.
BMD TH 0 0 D There is insufficient data to support a hypothesis: no study examined this
association.
BMD FN 2
[23,
27]
0 C We conclude a C level of evidence that there is no significant difference
between soy protein vs. animal protein intake on BMD loss in
postmenopausal women. Two RCTs with low ROB comparing isoflavone-
poor soy protein vs. animal protein did not find significant associations.
BMD TB 2
[23,
27]
0. C We conclude a C level of evidence that there is no significant difference
between soy protein vs. animal protein intake on BMD loss in
postmenopausal women. Two RCTs with low ROB comparing isoflavone-
poor soy protein vs. animal protein did not find significant associations.
BMC TB 0 0 D There is insufficient data to support a hypothesis: no study examined this
association.
Falls 0 0 D There is insufficient data to support a hypothesis: no study examined this
association.
Fractures 0 0 D There is insufficient data to support a hypothesis: no study examined this
association.
BSAP 2
[22,
23]
0 C We conclude a C level of evidence that there is no significant difference
between soy protein vs. animal protein intake on BSAP in postmenopausal
women. Two RCTs with medium ROB comparing isoflavone-poor soy
protein vs. animal protein did not find significant differences in the net
changes in BSAP.
CTX 0 0 D There is insufficient data to support a hypothesis: no study examined this
association.
DPD 0 0 D There is insufficient data to support a hypothesis: no study examined this
association.
NTX 2
[22,
23]
0 C We conclude a C level of evidence that there is no significant difference
between soy protein vs. animal protein intake on NTX in postmenopausal
women. Two RCTs with medium ROB comparing isoflavone-poor soy
protein vs. animal protein did not find significant differences in the net
changes in NTX.
1 BMD, bone mineral density; BMC, bone mineral content; BSAP, bone-specific alkaline phosphatase; CTX, C-
terminal telopeptide of type 1 collagen; DPD, deoxypyridinoline; FN, femoral neck; LS, lumbar spine; NTX, N-
terminal telopeptide of type 1 collagen; Ref, reference; TB, total body; TH, total hip; SOE, strength of evidence
https://doi.org/10.1371/journal.pone.0192459.t006
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outcomes (follow-up ranged from 3 to 13 years, S4 Table). Protein intake was assessed in all
studies using food frequency questionnaires (FFQs). Total plant and animal protein intake
were included in statistical models either separately as categorical or continuous variables
or together as a ratio (i.e., animal to plant protein intake ratio); and thus, none of these stud-
ies provide direct comparisons between plant and animal protein intake in relation to the
bone health outcomes. Of the 10 cohort studies, five reported BMD outcomes, six reported
fracture outcomes, and one reported fall outcome. The results are summarized in S5 Table.
Overall, most of cohort studies did not find statistically significant dose-response relation-
ships between levels of plant or animal protein intake and bone loss (as measured by changes in
BMD), and the associations between plant or animal protein intake and fracture outcomes were
inconsistent across studies. Only one study [37] examined the associations between plant and
animal protein intake and falls; the findings were not significant. Two cohort studies [28, 35]
showed an interaction between calcium and sources of protein intake on the risk of fracture,
with significant findings only among those with the lowest calcium intake (<417 mg/1000kcal
[28] and 800 mg/d [35]). Among those with the lowest calcium intake, both studies found those
in the highest animal protein quantile had significantly greater risk for fractures compared to
the lowest animal protein quantile [28, 35]; one study [28] found those in the highest plant pro-
tein quantile had significantly lower risk of fracture compared to the lowest plant protein quan-
tile, while the second study [35] reported no significant differences. Two studies examined the
ratio of animal to plant protein intake; one found a higher ratio of animal to plant protein intake
was associated with a higher risk of bone loss and hip fracture [36], while the second study
found no association with hip fracture [35].
Discussion and conclusions
Osteoporosis and low bone mass are a major health concern for an estimated 54 million Amer-
icans over the age of 50 years [38]. The relationship between dietary protein intake and the
type of protein consumed has been a topic of great debate over the past several decades. This
second systematic review, commissioned by the NOF, continues to further our understanding
of the relationship between dietary protein intake to markers of bone health by assessing if sig-
nificant differences in plant versus animal protein intakes exist.
Our systematic review found only C-level or “limited” evidence to suggest that there is no
significant difference between isoflavone-rich, isoflavone-poor, or animal protein at several
but not all BMD sites and the bone turnover markers NTX and BSAP. It is important to note
that one of the four studies examining the outcome NTX by Murray et al. [26] did not find a
significant difference in the net change of NTX between isoflavone-rich soy and animal pro-
tein groups. However, these negative findings are unsurprising considering the groups also
received estradiol; taking HRT or estradiol would likely mask any effect of dietary protein on
bone turnover and should be considered as a limiting factor on any dietary effect in future
study designs. D-level or “inadequate” evidence was assigned for several BMD sites, falls, and
fractures of any type, and thus no conclusions could be made regarding the effects of soy pro-
teins vs. animal proteins on these outcomes. D-level was also assigned for the bone turnover
markers CTX and DPD. One study [19] seemed to show an effect of higher SPI (91 mg/d) on
attenuating the bone marker CTX in estrogen-deficient women compared to animal protein;
this relationship should be considered as a direction for future studies.
Acid-producing diets are characterized by higher intakes of sulfur-containing amino
acids from protein and cereal grains in relation to intake of fruits and vegetables [39, 40].
These amino acids are metabolized to sulfuric acid; an increased dietary acid load can cause
low-grade metabolic acidosis and may lead to increased bone resorption and reduced bone
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mineral density [40]. In the Western world, the main contributors to the acid load from the
diet are meat, fish, milk and dairy products, and eggs, followed by cereal grains [41]. Con-
versely, base-producing diets, characterized by relatively higher intake of fruits and vegeta-
bles, are rich in organic anion salts that are metabolized to alkaline salts such as bicarbonate
[39, 42]. These metabolites can improve subclinical acidosis and may reduce bone turnover
and preserve bone [40, 42]. However, the acid-base balance effect on bone hypothesis has
been questioned on theoretical and experimental grounds because it was based on patients
with chronic kidney disease and may not extrapolate to healthy adults [43]. This review is
consistent with that interpretation of the literature. Though the included studies overall did
not report urine and blood protein levels, calcium excretion rate, or patient metabolic or
clearance rates, addressing them may be an interesting future research direction to better
understand response variability.
The state-of-the-science does not support that consumption of soy protein is more advanta-
geous on bone health outcomes as compared to animal proteins, or vice versa. All the included
studies used isolated soy protein as the plant protein source. This choice may be due to the fact
that soy protein, unlike most plant proteins, is a complete protein with high biological value
and thus more similar to animal protein [44]. However, as the doses of soy and animal protein
ranged from 18 to 40 g/d, some included studies may not have seen an effect due to the lower
doses of protein prescribed. Future studies should consider high versus low protein doses and
what protein dose may be needed to see an effect [45]. Future studies assessing intake of plant
proteins aside from soy, such as from beans, legumes, quinoa, or pea or brown rice protein
powders, as well as other animal proteins, such as from egg, are also needed to make generaliz-
able dietary guidance regarding “plant” vs. “animal” protein. Additionally, the included studies
focused on protein supplements; none of the included studies were total diet interventions or
took into account protein purity or dietary composition. Further investigation of the effect of a
variety of unrefined plant protein sources in the context of the food matrix compared to ani-
mal protein sources may be elucidating.
The effect of soy isoflavones on bone health has been recently reviewed [46]. Although
consumption of soy products containing isoflavones have been associated with protection
against hip fracture in Asia [47], several RCTs of isolated isoflavone preparations from soy
in the US have shown almost no benefit to BMD [48–50]. The difference in findings bet-
ween observational studies and RCTs has not been resolved, but differences in whole food
vs. isolated compounds, populations being studied, and methodological approaches have all
been considered.
None of the observational studies examined compared similar quantiles of plant and animal
protein intake. Given the typical Western diet, it is not surprising that the quantiles of plant pro-
tein intake reported in all studies were lower than those for animal protein intake. The compa-
rability of findings across observational studies was limited by these differing ranges within and
between studies, as well as by the varying definitions of “plant” and “animal” protein in the stud-
ies’ FFQs when assessing usual protein intake. It is also important to note the potential for mea-
surement error due to self-reported intake. Although these studies cannot directly answer the
question of this systematic review, future observational studies examining the effects of sources
of protein on bone health over long time periods can help generate future hypotheses for RCTs,
particularly in instances where there is a paucity of intervention studies (e.g., the effect of differ-
ent sources of protein intake on falls or fractures) and where intervention studies may be too
costly.
Lastly, though the interaction between protein sources and calcium intake were not a focus
of this systematic review, two of the cohort studies [28, 35] showed a significant interaction
between protein intake and calcium for those in the lowest calcium quantile. In both studies,
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those in the highest animal protein quantile had significantly greater risk of fractures com-
pared to those in the lowest animal protein quantile. Conversely, in one study [28] those in the
highest plant quantile had a significantly lower risk of fracture compared to those in the lowest
plant quantile, while the second study [35] reported no significant differences. Our previous
systematic review [6] examined interactions between high versus low protein intake and cal-
cium or vitamin D and found limited evidence did not support a synergistic effect of protein
with calcium on LS BMD, TH BMD or forearm fractures; there was insufficient evidence for
FN BMD and overall fracture outcomes. It thus may be of interest for future studies to take
into account the sources of dietary protein in relation to calcium intake.
In conclusion, the results of this systematic review do not support that consumption of soy
protein is more advantageous as compared to animal proteins, or vice versa. However, data for
bone health outcomes were C-level or “limited” at best, for some but not all markers of bone
health. There was insufficient evidence to draw conclusions regarding fractures and falls. We
found no adverse effects of either soy or animal proteins on bone health. However, all inter-
ventions administered protein supplements, had limited study durations and sample sizes, and
limited study populations to healthy, post-menopausal women. Larger, long-term RCTs and
properly designed prospective cohort studies comparing dose-response relationships of soy
and other plant proteins versus animal protein are greatly needed in the scientific literature.
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MJ, megajoule; NR, not report; NHANES, National Health and Nutrition Examination Survey;
NHS, Nurses’ Health Initiative; ref, reference; RR, relative risk; SD, standard deviation; SE, stan-
dard error; TB, total body; TEI, total energy intake; TH, total hip; Vit D, vitamin D; WHI, Wom-
en’s Health Initiative. 2 The association was examined in the supplemented group (calcium, Vit
D) only; i.e., not examined in placebo group. 3 Mean follow-up reported only. 4 The number of
women with incident fractures was reported and compared to fracture-free women. It is unclear
if some women had more than one fracture or if that was measured. 5 Reported protein intake
data are for N = 6510, not for the N = 4570 in the most adjusted model key findings reported
here.
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